SLC16A1 and neoplasm: RIVA did not appear dramatically different in the acute metabolite profile following combination treatment in comparison to sensitive tumour models, apart from a strong increase in α-ketoisocaproate, an intermediate of l-leucine metabolism and an MCT1 substrate [46].